Kevin S Shah1, Haolin Xu2, Roland A Matsouaka2, Deepak L Bhatt3, Paul A Heidenreich4, Adrian F Hernandez2, Adam D Devore2, Clyde W Yancy5, Gregg C Fonarow6. 1. Department of Medicine, Division of Cardiology, University of California, Los Angeles, Los Angeles, California. 2. Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina; Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina. 3. Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. 4. Division of Cardiology, Stanford University, Palo Alto, California. 5. Division of Cardiology, Northwestern University, Chicago, Illinois. 6. Department of Medicine, Division of Cardiology, University of California, Los Angeles, Los Angeles, California; Department of Medicine, Division of Cardiology/Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, Los Angeles, California. Electronic address: GFonarow@mednet.ucla.edu.
Abstract
BACKGROUND: Patients with heart failure (HF) have a poor prognosis and are categorized by ejection fraction (EF). OBJECTIVES: This study sought to characterize differences in outcomes in patients hospitalized with heart failure with preserved ejection fraction (HFpEF) (EF ≥50%), heart failure with borderline ejection fraction (HFbEF) (EF 41% to 49%), and heart failure with reduced ejection fraction (HFrEF) (EF ≤40%). METHODS: Data from GWTG-HF (Get With The Guidelines-Heart Failure) were linked to Medicare data for longitudinal follow-up. Multivariable models were constructed to examine 5-year outcomes and to compare survival to median survival of the U.S. RESULTS: A total of 39,982 patients from 254 hospitals who were admitted for HF between 2005 and 2009 were included: 18,299 (46%) had HFpEF, 3,285 (8.2%) had HFbEF, and 18,398 (46%) had HFrEF. Overall, median survival was 2.1 years. In risk-adjusted survival analysis, all 3 groups had similar 5-year mortality (HFrEF 75.3% vs. HFpEF 75.7%; hazard ratio: 0.99 [95% confidence interval: 0.958 to 1.022]; HFbEF 75.7% vs. HFpEF 75.7%; hazard ratio: 0.99 [95% confidence interval: 0.947 to 1.046]). In risk-adjusted analyses, the composite of mortality and rehospitalization was similar for all subgroups. Cardiovascular and HF readmission rates were higher in those with HFrEF and HFbEF compared with those with HFpEF. When compared with the U.S. population, HF patients across all age and EF groups had markedly lower median survival. CONCLUSIONS: Among patients hospitalized with HF, patients across the EF spectrum have a similarly poor 5-year survival with an elevated risk for cardiovascular and HF admission. These findings underscore the need to improve treatment of patients with HF.
BACKGROUND:Patients with heart failure (HF) have a poor prognosis and are categorized by ejection fraction (EF). OBJECTIVES: This study sought to characterize differences in outcomes in patients hospitalized with heart failure with preserved ejection fraction (HFpEF) (EF ≥50%), heart failure with borderline ejection fraction (HFbEF) (EF 41% to 49%), and heart failure with reduced ejection fraction (HFrEF) (EF ≤40%). METHODS: Data from GWTG-HF (Get With The Guidelines-Heart Failure) were linked to Medicare data for longitudinal follow-up. Multivariable models were constructed to examine 5-year outcomes and to compare survival to median survival of the U.S. RESULTS: A total of 39,982 patients from 254 hospitals who were admitted for HF between 2005 and 2009 were included: 18,299 (46%) had HFpEF, 3,285 (8.2%) had HFbEF, and 18,398 (46%) had HFrEF. Overall, median survival was 2.1 years. In risk-adjusted survival analysis, all 3 groups had similar 5-year mortality (HFrEF 75.3% vs. HFpEF 75.7%; hazard ratio: 0.99 [95% confidence interval: 0.958 to 1.022]; HFbEF 75.7% vs. HFpEF 75.7%; hazard ratio: 0.99 [95% confidence interval: 0.947 to 1.046]). In risk-adjusted analyses, the composite of mortality and rehospitalization was similar for all subgroups. Cardiovascular and HF readmission rates were higher in those with HFrEF and HFbEF compared with those with HFpEF. When compared with the U.S. population, HF patients across all age and EF groups had markedly lower median survival. CONCLUSIONS: Among patients hospitalized with HF, patients across the EF spectrum have a similarly poor 5-year survival with an elevated risk for cardiovascular and HF admission. These findings underscore the need to improve treatment of patients with HF.
Authors: Liping Zhou; Adrian Filiberti; Mary Beth Humphrey; Christian D Fleming; Benjamin J Scherlag; Sunny S Po; Stavros Stavrakis Journal: Exp Physiol Date: 2018-11-29 Impact factor: 2.969
Authors: Haider J Warraich; Dalane W Kitzman; David J Whellan; Pamela W Duncan; Robert J Mentz; Amy M Pastva; M Benjamin Nelson; Bharathi Upadhya; Gordon R Reeves Journal: Circ Heart Fail Date: 2018-11 Impact factor: 8.790
Authors: Ravi B Patel; Muthiah Vaduganathan; Aruna Rikhi; Hrishikesh Chakraborty; Stephen J Greene; Adrian F Hernandez; G Michael Felker; Margaret M Redfield; Javed Butler; Sanjiv J Shah Journal: JACC Heart Fail Date: 2018-11-05 Impact factor: 12.035
Authors: Laura P Gelfman; Yolanda Barrón; Stanley Moore; Christopher M Murtaugh; Anuradha Lala; Melissa D Aldridge; Nathan E Goldstein Journal: JACC Heart Fail Date: 2018-08-08 Impact factor: 12.035
Authors: Ambarish Pandey; Dalane Kitzman; David J Whellan; Pamela W Duncan; Robert J Mentz; Amy M Pastva; M Benjamin Nelson; Bharathi Upadhya; Haiying Chen; Gordon R Reeves Journal: JACC Heart Fail Date: 2019-12 Impact factor: 12.035
Authors: Jae Hyung Cho; Peter J Kilfoil; Rui Zhang; Ryan E Solymani; Catherine Bresee; Elliot M Kang; Kristin Luther; Russell G Rogers; Geoffrey de Couto; Joshua I Goldhaber; Eduardo Marbán; Eugenio Cingolani Journal: JCI Insight Date: 2018-10-04